May 04, 2026, 08:00 ETHEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASE
Kisunla™ (donanemab) is the first and only amyloid plaque-targeting therapy with evidence supporting stopping treatment once amyloid plaques are cleared. TORONTO, May 4, 2026 /CNW/ - Today, after...